Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 1

1(20.0%)

Phase 2

1(20.0%)

5Total

Phase 3(3)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT06207175Phase 3Unknown

A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine

Role: lead

NCT05694728Phase 2Completed

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

Role: lead

NCT05680454Phase 1Completed

A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine

Role: lead

NCT05668572Phase 3Unknown

A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine

Role: lead

NCT05662020Phase 3Active Not Recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Role: lead

All 5 trials loaded